AI assistant
Carasent Interim / Quarterly Report 2019
3568_rns_2020-02-12_6d7e77ac-4d54-4da1-a638-fc5aec14433e.pdf
Interim / Quarterly Report
Open in viewerOpens in your device viewer
Overview of Fourth Quarter 2019 consolidated results for Carasent ASA
- Revenues of NOK 14.1 million as compared to NOK 9.8 million during Q4-18
- Net income of NOK 0.4 million as compared to net loss of NOK 1.3 million during Q4-18
- Cash balances of NOK 10.9 million at December 31, 2019
Continued strong development for Evimeria EMR AB
- Revenue of SEK 18.5 million, an increase of 57 % as compared to Q4 2018 (Swedish GAAP)
- EBITDA of SEK 5.2 million as compared to SEK 1.5 million during Q4 2018 (Swedish GAAP)
- EBIT of SEK 4.3 million as compared to SEK 0.9 million during Q4 2018 (Swedish GAAP)
- Signed 20 new clinics during the Fourth Quarter 2019, which is in line with previous year. Ended the Fourth Quarter with 404 active clinics.
2019 performance
| Sign more than one clinic per week (1.5) |
> 78 | 89 | |
|---|---|---|---|
| Revenue growth (SEK and Swedish GAAP) |
50.0% | 50.1% | (37.7% IFRS) |
| Triple digit EBITDA growth (SEK, GAAP) |
100.0% | 101.0% | (100.2% IFRS) |
| Target | Actual | ||
|---|---|---|---|
Products and services
Q1-19
Q2-19
Q3-19
Q4-19
Financials
| EVIMERIA IFRS PROFORMA | 2 016 | 2 017 | 2 018 | 2 019 |
|---|---|---|---|---|
| Webdoc license | 9 928 | 13 967 | 19885 | 26 716 |
| Integrated Services | 7 312 | ਰੇ 326 | 14 130 | 19 875 |
| Consulting | 113 | 1 571 | 3 340 | 4 718 |
| Other | 75 | |||
| REVENUES | 17 352 | 24 864 | 37 325 | 51 385 |
| Growth% | 43,3% | 50,1% | 37,7% | |
| COGS | 3 869 | ਦੇ ਦੇਵੀ | 7516 | ਰੇ 388 |
| GROSS MARGIN | 13 484 | 19313 | 29 809 | 41 997 |
| GM % | 78% | 78% | 80% | 82% |
| OPEX | 8 953 | 13 586 | 21 108 | 24 579 |
| EBITDA | 4 531 | 5 727 | 8 700 | 17 417 |
| EBITDA% | 26,1% | 23,0% | 23,3% | 33,9% |
| D&A | 1 585 | 1 608 | 1 689 | 4 443 |
| EBIT | 2 946 | 4 120 | 7 012 | 12 975 |
| EBIT% | 17,0% | 16,6% | 18,8% | 25,2% |
| 50%+ CAGR EBIT GROWTH |
|---|
| 25%+ EBIT MARGINS |
| Proforma IFRS |
| Audited on Swedish GAAP (K2) |
Why do we win?
Web based and userfriendly interface
Cloud based Easy to implement
No upfront investments
Business model
Pay as you go – transparent with customer revenues
No long-term agreements
Integrated services
Covers all the businesscritical needs for our targeted segments
Focused
Products and services 100% developed to meet our segments needs Support process
Outlook
- To be transparent with the reporting of Carasent ASA, targets and proforma numbers for Evimeria EMR AB will, going forward, be translated into IFRS.
- Evimeria believes market conditions to remain strong in 2020 and expects the number of new clinics signed to increase as compared to actuals in 2019.
- Furthermore, we expect revenue growth in the 40% range (IFRS) as compared to actual 37.7% in 2019 and EBITDA margins (IFRS) in the 35-40% range as compared to actual 33.9% (IFRS) in 2019.